PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Entry into a Material Definitive Agreement

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry Into a Material Definitive Agreement.

Story continues below

On February 23, 2018, Provectus Biopharmaceuticals, Inc. (the “Company”) issued a secured convertible promissory note in favor of Timothy C. Scott, Ph.D. (“Scott”), the Company’s President, in the original principal amount of $250,000 (“Scott’s PRH Note”). The terms of Scott’s PRH Note are substantially identical to the terms of the notes the Company issued to a group of the Company’s stockholders (the “PRH Group”) to that certain Definitive Financing Commitment Term Sheet by and between the Company and the PRH Group, effective as of March 19, 2017 (individually a “PRH Note” and collectively, the “PRH Notes”). The terms of the PRH Notes were disclosed in the Company's Current Report on Form 8-K filed by the Company with the Commission on April 4, 2017. The foregoing description of Scott’s PRH Note does not purport to be complete and is qualified in its entirety by reference to Scott’s PRH Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

EX-10.1 2 ex10-1.htm   Note identifier PRH81   SECURED Convertible Promissory NOTE (this “Note”)   $250,…
To view the full exhibit click here


Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

An ad to help with our costs